,39 This is one of the reasons why therapeutic approaches directly targeting TDP-43 using ASOs have not been investigated to date and, therefore, it was unclear whether TDP-43 is an effective or appropriate target for ASO-based therapies against ALS/FTD as well as other TDP-43 proteinopathies. This evidence concerns the gene TARDBP and proteostasis deficiencies.